# US 2012/0251444 A1 · Treatment of liver disorders by administration of rap conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251444 A1
- Document ID: US20120251444A1
- Status: Published application
- Kind: A1
- Application number: 12/441,618
- Filed: 2007-09-18
- Published: 2012-10-04
- Earliest claimed: 2007-03-21
- Assignees: Raptor Pharmaceuticals Inc.
- Inventors: Christopher M. Starr; Todd C. Zankel
- Web page: https://patentgrep.com/patent/US20120251444A1

## CPC

- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 33/243: Platinum; Compounds thereof
- A61K 33/244: Lanthanides; Compounds thereof (medicinal preparations containing radioactive lanthanides for use in therapy or testing in vivo A61K51/00)
- A61K 38/168: {from plants}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61N 5/1001: {using radiation sources introduced into or applied onto the body; brachytherapy}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to the use of receptor-associate protein (RAP) and fragments and variants thereof to improve delivery of therapeutic compounds to the liver and provides methods to treat liver disorders and conditions, such as hepatic carcinoma, by administering RAP or RAP variants conjugated to active agents.

## Claims

### Claim 1

A method of treating a liver disorder in a subject comprising:
administering to said subject an effective amount of a conjugate comprising (a) a receptor binding moiety selected from the group consisting of Receptor Associated Protein of SEQ ID NO: 1 (RAP), RAP fragments, and RAP variants that retain RAP's binding affinity to LRP1 of about 1-5 nM, attached to (b) an active agent for treatment of liver disorder.

### Claim 2 (depends on 1)

The method of claim 1 wherein the receptor binding moiety of said conjugate is a RAP fragment or variant missing at least 200 and up to 243 amino acids from the N-terminus of SEQ ID NO: 1.

### Claim 3 (depends on 1)

The method of claim 1 wherein the receptor binding moiety of said conjugate is a RAP fragment missing at least 200 and up to 243 amino acids from the N-terminus of SEQ ID NO: 1.

### Claim 4 (depends on 2, 3)

The method of any of claims 2-3 wherein said RAP fragment or variant is missing 243 amino acids from the N-terminus of SEQ ID NO: 1.

### Claim 5 (depends on 2, 3, 4)

The method of any of claims 2-4 wherein said RAP fragment or variant is further missing at least 4 and up to 11 amino acids from the C-terminus of SEQ ID NO: 1.

### Claim 6 (depends on 2, 3, 4)

The method of any of claims 2-4 wherein said RAP fragment or variant is further missing 11 amino acids from the C-terminus of SEQ ID NO: 1.

### Claim 7 (depends on 1)

The method of claim 1 wherein said RAP fragment or variant lacks amino acids 1-143 and 320-323 of mature RAP of SEQ ID NO: 1.

### Claim 8 (depends on 2, 3, 4, 5, 6, 7)

The method of any of claims 2-7 wherein said RAP fragment or variant comprises a continuous portion of RAP d3 (SEQ ID NO: 2) that is (a) at least 71 amino acids in length and (b) comprises amino acids 256-270.

### Claim 9 (depends on 1)

The method of claim 1 wherein said receptor binding moiety is a cyclic RAP peptide that is less than about 85 amino acids in length, comprising 50 contiguous amino acids that are at least 70% identical to SEQ ID NO: 4, and which binds to LRP1 with a Kd of about 1×10−8 M or less.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any of claims 1-9 wherein said receptor binding moiety is a RAP variant, said RAP variant comprising one or more conservative substitutions relative to native RAP of SEQ ID NO: 1.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9 wherein said receptor binding moiety is a RAP variant, said RAP variant comprising a mutation at any one of positions 217, 249, or 251 of mature RAP.

### Claim 12 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 2-11 wherein said RAP variant comprises a mutation, wherein said mutation is the replacement of an acidic amino acid with a basic amino acid.

### Claim 13 (depends on 12)

The method of claim 12 wherein said acidic amino acid is selected from the group consisting of D and E.

### Claim 14 (depends on 12)

The method of claim 12, wherein said basic amino acid is selected from the group consisting of K and R.

### Claim 15 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method to any one of claims 2-11 wherein said RAP variant comprises a mutation, wherein said mutation is the replacement of a basic amino acid with an acidic amino acid.

### Claim 16 (depends on 15)

The method of claim 15, wherein said basic amino acid is selected from the group consisting of K and R.

### Claim 17 (depends on 15)

The method of claim 15, wherein said acidic amino acid is selected from the group consisting of D and E.

### Claim 18 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method to any one of claims 2-11 wherein said RAP variant comprises a mutation, wherein said mutation is the replacement of an amino acid selected from the group consisting of A, C, D, E, G, I, K, L, M, N, P, Q, R, S, T, and V with an amino acid selected from the group consisting of F, Y, W, and H.

### Claim 19 (depends on 1)

The method of claim 1 wherein the receptor binding moiety of said conjugate is a RAP fragment or variant set out in SEQ ID NO: 9.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any of claims 1-19, wherein the RAP, RAP fragment or RAP variant and diagnostic or therapeutic agent are linked through a linker.

### Claim 21 (depends on 20)

The method of claim 20, wherein said linker is a peptide linker.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21 wherein the receptor binding moiety is an oligomeric combination of RAP fragments or RAP variants.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any of claims 1-22 wherein the conjugate is in a pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any of claims 1-23, wherein the liver disorder is selected from the group consisting of hepatic cancer, hepatitis, cirrhosis, fungal, rickettsial or parasitic infections, alcohol, chemical toxins, damage due to drug toxicity, metabolic liver disease, idiopathic autoimmune liver disease, biliary obstruction, hepatic steatis, cholestasis, and post-hepatectomy conditions.

### Claim 25 (depends on 24)

The method of claim 24 wherein the hepatic cancer is selected from the group consisting of hepatocellular carcinoma and the active agent moiety is a cytotoxic chemotherapeutic agent.

### Claim 26 (depends on 24)

The method of claim 24, wherein the disorder is a liver tumor or tumor metastases in the liver, and the therapeutic agent is a chemotherapeutic agent.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26 wherein the active agent is a cytotoxic agent.

### Claim 28 (depends on 27)

The method of claim 27 wherein the cytotoxic agent is selected from the group consisting of Mechlorethamine hydrochloride, Cyclophosphamide, Ifosfamide, Chlorambucil, Melphalan, Busulfan, Thiotepa, Carmustine, Lomustine, Dacarbazine and Streptozocin.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26 wherein the active agent is a radioisotope.

### Claim 30 (depends on 29)

The method of claim 29 wherein the radioisotope is selected from the group consisting of 131I, 125I, 111In, 90Y, 67Cu, 127Lu, 212Bi, 213Bi, 255Fm, 149Tb, 223Rd, 213Pb, 212Pb, 211At, 89Sr, 153Sm, 166Ho, 225Ac, 186Re, 67Ga, 68Ga and 99mTc.

### Claim 31 (depends on 24)

The method of claim 24, wherein the disorder is hepatitis caused by a virus, and the therapeutic agent is an antiviral agent.
